

Second Quarter 2022 Management Discussion and Analysis

Six months ended March 31, 2022

(expressed in thousands of Canadian dollars)

Dated: May 26, 2022



ENWAVE CORPORATION ("EnWave" or the "Company")

MANAGEMENT DISCUSSION AND ANALYSIS SECOND QUARTER FOR THE SIX MONTHS ENDED MARCH 31, 2022

Date of this report: May 26, 2022

This Management's Discussion and Analysis ("MD&A") provides a review of EnWave Corporation's ("EnWave", "the Company", "we", "us" or "our") financial performance, on a consolidated basis, for the six months ended March 31, 2022 relative to the six months ended March 31, 2021, and the financial position of the Company at March 31, 2022 relative to September 30, 2021. It should be read in conjunction with EnWave's unaudited condensed consolidated interim financial statements and accompanying notes for the three and six months ended March 31, 2022 ("Q2-2022") and 2021 ("Q2-2021"), as well as the 2021 annual MD&A and the 2021 annual audited consolidated financial statements and accompanying notes, and the 2021 Annual Information Form ("AIF") (available at <u>www.enwave.net</u> or on <u>www.sedar.com</u>). The financial information contained in this MD&A has been prepared in accordance with International Financial Reporting Standards ("IFRS"), which is the required reporting framework for Canadian publicly accountable enterprises.

All financial references are in thousands of Canadian dollars unless otherwise noted.

Management's Responsibility for Financial Information

The Company's management is responsible for the presentation and preparation of the condensed consolidated interim financial statements and the MD&A. The condensed consolidated interim financial statements have been prepared in accordance with IFRS.


The MD&A has been prepared in accordance with the requirements of securities regulators, including National Instrument 51-102 of the Canadian Securities Administrators.

The condensed consolidated interim financial statements and information in the MD&A necessarily include amounts based on informed judgements and estimates of the expected effects of current events and transactions with appropriate consideration to materiality. In addition, in preparing the financial information we must interpret the requirements described above, make determinations as to the relevancy of information to be included, and make estimates and assumptions that affect reported information. The MD&A also includes information regarding the impact of current transactions and events, sources of liquidity and capital resources, operating trends, risks and uncertainties. Actual results in the future may differ materially from the present judgements and estimates.

Company Overview

Radiant Energy Vacuum ("REV[™]") Technology

EnWave is an applied dehydration technology company that licenses its intellectual property and manufactures commercial-scale proprietary dehydration equipment for applications in the food, cannabis and pharmaceutical sectors. EnWave has entered into **49 royalty-bearing commercial licenses** with and sold REV[™] equipment to a diverse portfolio of companies operating in over 21 different countries on five continents. EnWave also operates REVworx[™], a toll processing facility located in Delta, B.C., that offers vacuum microwave contract manufacturing services. The REVworx[™] facility houses both a batch 10kW and 60kW continuous vacuum microwave line to accelerate the commercialization of products made with EnWave's patented technology.



ΝΨΛΥΕ

F

EnWave's mission is to establish its REV[™] technology as a new global dehydration standard. By selectively collaborating with strategic partners focused on creating new or improved product opportunities, increasing throughputs and/or reducing processing costs the Company is developing markets for its REV[™] technology. Management believes that REV[™] technology can produce products with better quality than air-drying, spray-drying and freeze-drying. REV[™] technology is also typically faster and more economical than freeze-drying.

EnWave's core business model is to secure multiple, diversified royalty streams through the licensing of its technology. As part of this strategy, EnWave has four primary revenue streams:

- 1. Equipment Sales. EnWave manufactures and sells REV[™] equipment built at its fabrication facility in Delta, British Columbia. The Company offers machinery in a variety of sizes, from 10kW batch units through to 120kW large-scale, continuous processing lines.
- 2. Royalties and Licensing Fees. The Company enters royalty-bearing commercial license agreements with companies that utilize REV[™] equipment for commercial production. Each license grants the royalty partner access to EnWave's intellectual property portfolio comprising the Company's patents, know-how and trade secrets. The commercial license agreements stipulate royalty payments to be made on a quarterly basis based on a percentage of sales generated or a fee per unit produced from the use of the REV[™] technology. In certain cases, the royalty structure can take the form of pre-agreed payments not tied to sales or units produced but equate to a targeted annual royalty amount per REV[™] machine capacity. The licenses also restrict the royalty partner's commercial use of the technology to specific products within a limited geographic territory. Royalty partners are typically free to sell their REV[™] dried products wherever they are legal to be sold.
- 3. Equipment Rentals. EnWave rents pilot-scale 10kW REV[™] units to companies evaluating the Company's patented technology for desired product applications. The rental terms are typically less than a year in duration and the objective is to allow prospective royalty partners to develop products using REV[™] technology prior to entering into a license agreement. Many companies often purchase the machine supplied to them during the evaluation period to initiate royalty-bearing commercial production.
- 4. Toll Manufacturing. The Company has recently launched a toll manufacturing division called REVworx[™] to accelerate the commercialization of more food products using REV[™] technology. The toll manufacturing operation contains commissioned pilot-scale and large-scale REV[™] equipment to utilize the installed capacity to produce commercial products on a fee-for-service basis. This new division is intended to complement the current equipment sales and royalty-licensing business model of the Company and serve as a lower barrier entry point for consumer packaged goods ("CPG") companies seeking to market trial REV[™]-dried products. The facility opened for commercial production in March 2022.

EnWave's dehydration technology is currently being used to produce commercial applications in multiple market verticals, including fruits and vegetables, dairy products, ready-to-eat meals (including instant noodles), baked goods, cannabis products, nutraceuticals, and pharmaceuticals. The Company's strategy with respect to existing royalty partners is to collaborate closely with them to develop and commercialize products using REV[™] technology and build demand for increased production capacity, which will lead to more equipment sales and ultimately growth in royalty streams.

The Company is actively engaged in many commercially focused research and development projects to expand the number of viable REV[™]-dried products and to expand the use of REV[™] into additional markets.



NutraDried Food Company

The Company's wholly owned subsidiary, NutraDried Food Company, LLC ("NutraDried"), is a limited liability corporation registered in Washington, USA. NutraDried manufactures and sells Moon Cheese[®], an all-natural dried cheese snack in several formats produced using REV[™] technology. NutraDried also co-manufactures REV[™]-dried cheese for sale in bulk as an ingredient or inclusion for third-party brands. NutraDried currently produces REV[™]-dried cheese using two 100kW nutraREV[®] machines at its manufacturing facility located in Ferndale, Washington State. Moon Cheese[®] is sold in over 25,000 retail locations across Canada and the United States. Notable retail points of distribution currently include Starbucks, Publix, Safeway/Albertsons, Food Lion, Rite Aid and CVS, Costco, among others.

NutraDried has demonstrated the ability for REV[™] technology to operate reliably at scale. This subsidiary began as a proof-of-concept, as it showcased the capabilities of large-scale commercial REV[™] machinery to potential royalty partners and has grown into a growing snack business. Furthermore, NutraDried's business model has established a precedent for analysis by dairy companies considering the commercialization of innovative, shelf-stable dairy snacks. The Company's strategy is to grow NutraDried's business through increased retail distribution, online distribution and introducing new, innovative product extensions into its portfolio. The Company also seeks to supply third-party brands with bulk shelf-stable cheese ingredients for use in mixes and other products.

NutraDried holds a commercial license for REV[™] technology and pays a royalty to EnWave based on its revenue. The royalties from NutraDried, a subsidiary of EnWave, are eliminated from revenue in the consolidated financial statements of the Company.

(\$ '000s)	Jun 30,	Sep 30,	Dec 31,	Mar 31,	Jun 30,	Sep 30,	Dec 31,	Mar 31,
	2020	2020	2020	2021	2021	2021	2021	2022
NutraDried Royalty ⁽¹⁾	236	670	340	166	218	181	137	341

The quarterly royalty payments from NutraDried to EnWave were as follows:

(1) The royalty payment to EnWave is an intercompany transaction that is eliminated upon consolidation from revenue as reported in the Company's condensed consolidated interim financial statements and is a non-IFRS financial measure. Please refer to the disclosures under the heading *Non-IFRS Financial Measures*.

Recent Developments

Injunction Application Granted

On April 4, 2022, EnWave received a written reasoning from the B.C. Supreme Court granting an injunction application against the former CEO, Timothy Durance, his companies, and affiliates. EnWave's injunction application was filed on July 30, 2021, requesting Timothy Durance, his companies and affiliates be restrained from selling or supplying vacuum microwave products pending trial. EnWave's injunction hearing was heard in B.C. Supreme Court from January 17 to 20, 2022. The written reasoning states that the injunction will remain in place until the trial of EnWave's actions which is scheduled for September 2023.

EnWave Launches REVworx[™]

The Company recently completed construction of its vacuum-microwave toll drying facility REVworx[™]. A 60kW REV[™] machine and 10kW REV[™] machine have been installed, as well as medium scale air dryer and other food processing equipment to provide contract manufacturing services. REVworx[™] can be used to produce high-quality, vacuum-microwave dried snack and ingredients applications for food companies of all sizes. It will allow companies to bring innovative vacuum-microwave dried products to market in a shorter timeframe and will reduce new product introduction risk by lowering the upfront investment. The Company is in the process of obtaining Safe Quality Food ("SQF") certification

and is in discussions with several prospects for its first commercial manufacturing arrangement. The Company has several prospects considering REVworx[™] to launch new products to market and is seeking to confirm tolling agreements in the near term to utilize capacity.

Cannabis Drying Patent Granted in U.S.

The U.S. Patent and Trademark Office granted the Company a new method and apparatus patent for the drying and decontamination of cannabis using REV[™] technology. This new patent further strengthens EnWave's intellectual property protection of its method of reducing bioburden in cannabis while concurrently achieving fast, uniform drying. EnWave's patented process uses proven parameters, including power density and vacuum conditions that vary throughout the process, to optimize terpene and cannabinoid retention and materially reduce bioburden.

Overall Performance

For Q2 2022, the Company had consolidated revenues of \$6,881 compared to \$4,686 for Q2 2021, an increase of \$2,195 or 47%. For the first two quarters of fiscal 2022, the Company had consolidated revenues of \$13,178, compared to \$12,219 in the same period in fiscal 2021, an increase of \$959 or 8%. The Company had a consolidated net loss of \$2,639 in the six months ended March 31, 2022, compared to a consolidated net loss of \$3,657 for the same period in 2021, an improvement of \$1,018.

The Company reported an Adjusted EBITDA^(*) loss of \$1,218 for Q2 2022, compared to an Adjusted EBITDA^(*) loss of \$1,968 for Q2 2021, a reduction of \$750. For the six months ended March 31, 2022, the Company reported an Adjusted EBITDA^(*) loss of \$917, compared to a \$2,879 loss for the six months ended March 31, 2021, an improvement of \$1,962. The EnWave segment reported a positive Adjusted EBITDA^(*) which was offset by NutraDried's Adjusted EBITDA^(*) loss for the six months ended March 31, 2022.

For the six months ended March 31, 2022, EnWave reported revenues of \$5,561 compared to \$5,024 for the six months ended March 31, 2021, an increase of \$537. EnWave's revenues were higher due to more machine fabrication revenue, paired with higher royalty revenue. EnWave reported a segment loss of \$716 for the six months ended March 31, 2022, compared to positive segment income of \$17 for the six months ended March 31, 2021, a decrease of \$733.

NutraDried reported revenues of \$7,617 for the six months ended March 31, 2022, compared to \$7,195 for the six months ended March 31, 2021, an increase of \$422 or 6%. NutraDried reported a segment loss of \$1,923 for the six months ended March 31, 2022, compared to a segment loss of \$3,674 for the six months ended March 31, 2021, an improvement of \$1,751. NutraDried sales increased due to increased distribution for its Moon Cheese[®] branded product portfolio.

(*) Adjusted EBITDA is a non-IFRS Financial Measure. Please see the "Non-IFRS Financial Measures" section for more information.

Commercial Licensing and Partnership Development

Installation of Patatas Fritas Torres 100kW Machine in Spain

In January 2022, the Company completed the installation of a 100kW REV[™] machine for Patatas Fritas Torres ("Torres") in Spain. Torres has scaled-up manufacturing capacity for its lineup of shelf-stable cheese snacks marketed under its "Just This" brand (<u>https://justthis-snacks.com/en/</u>).

Equipment Purchase Agreement with Fresh Business

On January 27, 2022, the Company signed an equipment purchase agreement with Consulting Fresh Business ("Fresh Business") for a 10kW REV™ machine to be installed in Spain. Fresh Business plans to use the machine to conduct intensive research and development on REV™-dried products to identify new commercial opportunities to leverage EnWave's technology in Western Europe. Fresh

Business also has a 10kW machine and 100kW machine installed in Peru, where it produces a line of premium fruit and vegetable products under its NXTDRIED[™] brand (<u>https://www.nxtdried.com/</u>).

Equipment Purchase Agreement with Orto Al Sole

On February 16, 2022, the Company signed an equipment purchase agreement with Orto Al Sole Societa Agricola ("Orto Al Sole"), its Italian royalty partner, for a large-scale 120kW REV[™] machine. Orto Al Sole scaled-up its royalty-bearing manufacturing capacity for its product line of healthy, better-for-you snacks made using REV[™] technology based on growing demand and distributed across Europe.

Dole Acquisition of Second 10kW Machine

On February 22, 2022, the Company announced that Dole Worldwide Food and Beverage Group, a division of Dole Asia Holdings Pte Ltd. ("Dole") acquired a second 10kW REV[™] machine under a leasing arrangement to expand its production capacity of REV[™]-dried products for the planned market trials. If market trials are successful, Dole will require large-scale REV[™] equipment to launch its new products.

Equipment Purchase Agreement with Nomad Nutrition

On March 3, 2022, the Company signed a second equipment purchase agreement with Nomad Nutrition Ltd ("Nomad"), for another 10kW REV[™] machine. Nomad has doubled its commercial production capacity for it's Ready-to-Eat adventure meals made using REV[™] technology as the meals gain in popularity.

Technology Evaluation and License Option Agreement with Goldencrops

On May 3, 2022, the Company signed a Technology and Evaluation License Option Agreement with Goldencrops Corporation, a Southeast Asian ingredient manufacturer. Goldencrops is evaluating REV[™] technology to produce a variety of fruit, dairy and grain products. Goldencrops will rent a 10kW REV[™] machine placed in Douliu, Taiwan during the term of the evaluation.

Royalty Partner and REV[™] Machine Sales Pipeline

The Company rents REV[™] machinery to companies evaluating the technology for specific product applications under Technology Evaluation and License Option Agreements ("TELOAs"). The strategy under these arrangements is to co-develop product applications using the technology for specific partner opportunities and to ultimately convert TELOAs into commercial licenses. EnWave earns revenue under TELOAs from short-term REV[™] machine rentals as well as fees for access to EnWave's R&D facilities and product development expertise. EnWave's food scientists and engineers work with the prospective licensees during the term of the TELOA to formulate and optimize innovative products using REV[™], and to develop a path towards commercialization.

EnWave's current sales pipeline comprises multiple companies that have entered TELOAs as well as many earlier-stage prospects that are in active discussions about using REV[™] under mutual nondisclosure agreements. Prospective licensees have the option of bypassing the TELOA phase and entering directly into a commercial license agreement to purchase REV[™] machinery. This is often the case when the product application has been previously proven commercially, or when the value proposition and business case are compelling enough for the prospect to enter directly into commercial production.

EnWave has a dedicated sales and marketing team focused on growing the number of commercial license agreements and securing new TELOAs. As of the date of this report, EnWave has **six TELOAs** with prospective licensees evaluating the use of REV[™].



Machine Fabrication and Installation Pipeline:

The table below summarizes the current fabrication and commissioning schedule of machines purchased by EnWave licensees under Equipment Purchase Agreements as of the date of this MD&A:

Licensee	Machine Capacity	Licensed Product	Territory
BranchOut	60kW	Fruits and Vegetables	Americas
Cannaponics	10kW GMP	Cannabis	Australia
Australian Cannabis Company	10kW GMP	Cannabis	Australia
Cannabis Multi-State Operator	120kW	Cannabis	USA
Cannabis Single-State Operator	120kW	Cannabis	USA
Dairy Concepts	10kW	Dairy	Ireland ⁽¹⁾
Fresh Business	10kW	Fruits and Vegetables	Spain ⁽¹⁾
Orto Al Sole	120kW	Fruits and Vegetables	Italy
Nomad Nutrition	10kW	Ready-to-Eat Meals	Canada

Note:

(1) The machine has been fabricated by the Company and delivered to the royalty partner's site and EnWave is to complete the installation and training.

NutraDried Food Company

Sales of Moon Cheese[®] in Q2 2022 were lifted by a national program with Costco Canada that shipped early in the quarter. Grocery channel sales also increased in Q2 2022 with Kroger stocking 3 SKUs nationally across 2,200 stores in the U.S. The grocery channel is the priority focus for NutraDried and club opportunities are also being pursued strategically.

NutraDried recently launched Moon Cheese[®] Crunchy Sticks, an all-natural cheese stick snack that is the first shelf-stable cheese snack product in a stick or puff format made from 100% real cheese. Moon Cheese[®] Crunchy Sticks is being offered in five flavours: Cheesy Does It (cheddar), Rowdy Ranch (zesty ranch), Wild White Chedda' (white cheddar), Yum Inferno (spicy) and Kick It Up a Nacho (nacho). The official launch took place at Natural Products Expo West in Anaheim, California in March and customer presentations for Moon Cheese[®] Crunchy Sticks are underway. NutraDried has already confirmed new distribution for Crunchy Sticks in Whole Foods Market and Walmart and is seeking to gain further new distribution over the coming months.

NutraDried produces and sells dried cheese in bulk format for ingredient applications to third-party brands for use in mixes and other snack products. The management team continues to pursue new bulk, private label and contract manufacturing opportunities to diversify and grow NutraDried's revenue base.

NutraDried aims to continue to grow its distribution nationally in the U.S. and is targeting numerous new retailers and new product lines as part of its strategy. The Company's objective is to continue to grow its core distribution in the U.S. retail grocery channel by securing new national retail accounts and smaller regional accounts. NutraDried has confirmed new distribution for Moon Cheese[®] in several major retailers in the U.S. such as Kroger, Whole Foods Market and Walmart. NutraDried previously announced that Target would expand Moon Cheese to all its U.S. stores; however, this expansion has since been put on hold while the Company works toward a revised plan with this retailer.



Cheese Pricing

NutraDried is exposed to commodity price fluctuations for block cheese, its primary raw material input cost. The commodity pricing of bulk cheese has increased over the last several months, which has impacted gross margin. Cheese pricing for a 40-pound cheddar block on the Chicago Mercantile Exchange went from US\$1.79/lb in October 2021 to US\$2.23/lb in March 2022, and is in the US\$2.40/lb range as of the date of this report. The volatility in cheese pricing impacts NutraDried's cost of goods sold, and when possible uses forward contracts to mitigate the impacts of commodity price fluctuations.

Summarized Quarterly Results

The following is a selected summary of quarterly results for the eight most recently completed quarters to March 31, 2022, reported in Canadian dollars, the Company's presentation currency:

	202	20		20	21		202	22
(\$ '000s)	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2
Revenues	5,998	10,784	7,533	4,686	7,351	6,906	6,297	6,881
Direct costs	(4,441)	(8,629)	(5,835)	(4,208)	(4,737)	(4,529)	(3,581)	(5,538)
Gross profit	1,557	2,155	1,698	478	2,614	2,377	2,716	1,343
Expenses	(3,542)	(3,184)	(3,764)	(3,965)	(2,239)	(3,370)	(3,116)	(3,729)
Other income	690	929	325	483	225	306	147	-
Income tax (expense) recovery	129	101	370	718	70	(451)	-	-
Net (loss) income after income tax	(1,166)	1	(1,371)	(2,286)	670	(1,138)	(253)	(2,386)
Adjusted EBITDA ⁽¹⁾	(1,034)	20	(911)	(1,968)	937	(223)	301	(1,218)
Loss per share – Basic and diluted	(0.01)	(0.00)	(0.01)	(0.02)	0.00	(0.01)	(0.00)	(0.02)
Total assets	38,190	40,663	34,633	33,301	32,568	30,641	29,990	29,362
Total liabilities	9,885	12,312	7,622	8,427	7,224	7,653	7,047	8,519

(1) Adjusted EBITDA is a non-IFRS Financial Measure. Please see the "Non-IFRS Financial Measures" section for more information.

EnWave's revenues, direct costs and net loss fluctuate based on the timing of machine orders from companies in our sales pipeline. Management works closely with each company evaluating REV[™] technology under TELOAs and R&D projects but is not able to accurately predict the timing and frequency of machine orders. The revenue in any given period will vary depending on the number of machine orders received and new licenses signed, and this causes variability in our quarterly financial performance. Additionally, the Company generates royalty revenues each quarter from the installed REV[™] equipment base with its royalty partners but does not have the ability to direct or control the commercial launch, royalty growth or seasonality of each partner's product offering, resulting in fluctuations in the royalties earned by the Company each quarter.

Revenues and gross profit also vary from quarter to quarter depending on the timing of Moon Cheese[®] product rotations at Costco, a major customer historically and the timing of machine fabrication revenues. Revenues for Q2 2022 were higher than Q1 2022 and Q2 2021 due to Moon Cheese[®] sales to Costco Canada. Revenues in Q4 2020 were higher due to a national promotion NutraDried ran in Costco U.S. Revenues from EnWave were lower in Q2 2022 than Q1 2022 due to lower machine sales revenues. Revenues for EnWave were lower in Q2 2022 compared to Q2 2021 due to lower machine sales activity in the period.



Direct costs for Q1 2022 increased relative to prior quarters with a shift in sales mix to more NutraDried revenues, which are typically at a lower margin. Additionally, cheese pricing in Q2 2022 increased relative to previous quarters and contributed to higher direct costs at NutraDried. Direct costs for Q1 2022 were lower than Q2 2022 and each of the preceding quarters with additional contribution from EnWave reselling a large-scale REV[™] machine for additional margin.

The Company's expenses increased slightly in Q2 2022 from Q1 2022 primarily due additional travel and tradeshow expenses, along with start-up costs for REVworx[™]. Expenses were lower than Q2 2021 due to NutraDried's severance costs for restructuring in Q2 2021 not recurring. Adjusted EBITDA⁽¹⁾ was negative for Q2 2022 and Q1 2021 due to timing of fabrication on customized machines and decreased machine sales for EnWave. Adjusted EBITDA⁽¹⁾ was positive for Q1 2022 due to an improved contribution from machinery sales at EnWave offset by NutraDried's loss.

Selected Financial Information

The following table sets out selected consolidated financial information for the periods indicated and has been derived from EnWave's condensed consolidated interim financial statements and accompanying notes for the three and six months ended March 31, 2022 and 2021, and should be read in conjunction with those financial statements.

(\$ '000s)	Three mo	nths ended N		Six months ended March 31,		
	2022	2021	Change %	2022	2021	Change %
Revenues	6,881	4,686	47%	13,178	12,219	8%
Direct costs	5,538	4,208	32%	9,119	10,043	(9%)
Gross margin	1,343	478	181%	4,059	2,176	87%
Operating expenses						
General and administration	1,190	1,214	(2%)	2,308	2,340	(1%)
Sales and marketing	1,449	1,304	11%	2,581	2,825	(9%)
Research and development	600	463	30%	1,177	1,032	14%
	3,239	2,981	9%	6,066	6,197	(2%)
Net loss after taxes	(2,386)	(2,286)	(4%)	(2,639)	(3,657)	28%
Adjusted EBITDA ⁽¹⁾	(1,218)	(1,968)	38%	(917)	(2,879)	68%
Loss per share – basic and diluted	\$ (0.02)	\$ (0.02)		\$ (0.02)	\$ (0.03)	

(1) Adjusted EBITDA is a non-IFRS financial measure. Please see the "*Non-IFRS Financial Measures*" section for more information, including a reconciliation to net loss.



Discussion of Operations

Revenue

Revenue is earned from two business segments: EnWave and NutraDried. EnWave generates revenue from the sale of REV[™] machinery to royalty partners, rental revenue from short-term rentals of REV[™] machinery to prospective royalty partners, and royalties earned from commercial license agreements. EnWave anticipates generating revenue from toll manufacturing services starting in fiscal 2022. NutraDried generates revenue from the sale of Moon Cheese[®] into retail and wholesale distribution channels, as well as for sale as bulk for ingredient purposes.

	Three months end	ed March 31,	Six months end	ed March 31,
(\$ '000s)	2022	2021	2022	2021
Revenue	6,881	4,686	13,178	12,219

Revenue for the six months ended March 31, 2022, was \$13,178, compared to \$12,219 for the six months ended March 31, 2021, an increase of \$959. Revenue for the three months ended March 31, 2022, was \$6,881, an increase of \$2,195 compared to the three months ended March 31, 2021. The increase in revenues for the six months ended March 31, 2022, is primarily due to a program at Costco Canada for Moon Cheese[®] and increased purchase order volume for large-scale machinery in the first quarter of 2022 relative to 2021. The timing and frequency of each large-scale commercial machine order affects the timing of our revenues from the sale of REV[™] machinery.

Quarterly Revenue	202	2020		2021			202	22
(\$ '000s)	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2
EnWave	1,609	1,601	2,676	2,348	3,560	3,879	4,067	1,494
NutraDried	4,389	9,183	4,857	2,338	3,791	3,027	2,230	5,387
Total	5,998	10,784	7,533	4,686	7,351	6,906	6,297	6,881

Revenues from EnWave were \$5,561 for the six months ended March 31, 2022 compared to \$5,024 for the six months ended March 31, 2021, an increase of \$537. The increase was due to a combination of higher machinery sales and royalty growth. Revenues from EnWave were \$1,494 for the three months ended March 31, 2022, compared to \$2,348 for the three months ended March 31, 2021, a decrease of \$854 due to lower machinery sales in Q2 2022 relative to the prior year.

EnWave continues to pursue revenue growth through commercial machine sales and by signing new royalty-bearing licenses that are accompanied by machine purchase orders. The REVworx[™] division has recently started up and revenues from REVworx[™] tolling agreements are expected to commence in the latter half of 2022. Revenue for EnWave is contract-based and is not considered seasonal; however, fluctuations in revenue will occur based on the magnitude and volume of commercial equipment sales contracts open during a given period.

EnWave reported royalties of \$750 for the six months ended March 31, 2022, compared to \$483 for the six months ended March 31, 2021, an increase of \$267 or 55%. The growth in royalties in Q2 2022 reflects the increase in large-scale machines installed for commercial production of royalty-bearing products as well as more annual exclusivity retention payments collected at the end of the calendar year. Royalties are payable to EnWave as a percentage of the value of products sold or based on the number of units produced by our royalty partners. The Company's royalties experience some seasonality due to the timing of annual minimum royalty payments required under its commercial license agreements to retain licensing exclusivity.

Revenues from NutraDried were \$7,617 for the six months ended March 31, 2022, compared to \$7,195 for the six months ended March 31, 2021, an increase of \$422. The increase in revenues for the six



months ending March 31, 2022 was primarily due to a Costco Canada Moon Cheese[®] rotation in Q2 of 2022 in combination with a slight increase in sales to other retailers due to new distribution.

Direct costs

Direct costs comprise the cost of materials, packaging, components, manufacturing labour, overhead costs, depreciation of manufacturing plant and equipment, inventory write-offs, warranty costs and product transportation costs. Direct costs comprise all direct costs related to the revenue generating operations of the Company.

	Three months ende	Three months ended March 31,		
(\$ '000s)	2022	2021	2022	2021
Direct costs	5,538	4,208	9,119	10,043
% of revenue	80%	90%	69%	82%

Direct costs for the six months ended March 31, 2022, decreased by \$924, or 9%, compared to the six months ended March 31, 2021. Direct costs for the three months ended March 31, 2022, were \$5,538 compared to \$4,208 for the three months ended March 31, 2021, an increase of \$1,330. As a percentage of revenue, direct costs for the three months ended March 31, 2022 decreased by 10%, and for the six months ended March 31, 2022, decreased by 13% compared to March 31, 2021.

Direct costs for EnWave are driven by direct material and overhead costs associated with commercial machine selling and construction activity. During the six months ended March 31, 2022, EnWave yielded a ratio of direct costs to revenue of 49%, compared to 62% for the six months ended March 31, 2021. The increase in gross margin was due to the sale of one large machine that was repurchased from a cannabis partner, resulting in a lower direct cost. Input costs for machine fabrication have increased in recent months, with the cost of stainless steel and componentry rising. Higher manufacturing costs have been offset by growth in the high-margin royalty revenues, resulting in improved gross margin.

The ratio of direct costs to revenue was 62% for NutraDried for the six months ended March 31, 2022, compared to 98% in the six months ended March 31, 2021, a decrease of 36%. The improvement to gross margin was a result of not repeating the discounted MVM program with Costco in 2022 that was ran in 2021, which was partially offset by higher cheese prices.

Direct costs of NutraDried are highly dependent on the commodity pricing of raw cheese as the primary raw material used in production. Cheese prices increased during the six months ended March 31, 2022, and the commodity price fluctuations of cheese have compressed margins at NutraDried. The Company implemented a price increase on its products that will take effect in May 2022 in an effort to offset rising input costs. We continuously monitor the impact of commodity price fluctuations and may employ hedging tactics, where appropriate, to mitigate risk.

General and administration

General and administration ("G&A") expenses consist of wages, administration, accounting and audit fees, legal fees, investor relations, depreciation, insurance, and other corporate expenses.

	Three months ende	ed March 31,	Six months ended March 31,	
(\$ '000s)	2022	2021	2022	2021
General and administration	1,190	1,214	2,308	2,340
% of revenue	17%	26%	18%	19%

G&A expenses for the six months ended March 31, 2022, were \$2,308 compared to \$2,340 for the six months ended March 31, 2021, a small decrease of \$32. G&A expenses for the three months ended March 31, 2022, were \$1,190 compared to \$1,214 for the three months ended March 31, 2021, a



decrease of \$24. In general, the Company has not significantly adjusted its G&A spending relative to the prior year, and the cost containment measures implemented at NutraDried in Q2 2021 remain in place.

Sales and marketing

Sales and marketing ("S&M") expenses include salaries and wages, travel expenses, consulting fees, promotional and marketing fees, commissions, agency fees, and office expenses related to selling and marketing activities.

	Three months ende	ed March 31,	Six months ended March 31,	
(\$ '000s)	2022	2021	2022	2021
Sales and marketing	1,449	1,304	2,581	2,825
% of revenue	21%	28%	20%	23%

S&M expenses for the six months ended March 31, 2022, were \$2,581 compared to \$2,825 for the six months ended March 31, 2021, a decrease of \$244. The decrease is attributed to lower use of marketing agencies and personnel costs at NutraDried, which was offset by attendance at tradeshows and business development travel. S&M expenses for the three months ended March 31, 2022, were \$1,449 compared to \$1,304 for the three months ended March 31, 2021, an increase of \$145.

S&M expenses for EnWave were \$1,105 for the six months ended March 31, 2022, compared to \$562 for the six months ended March 31, 2021, an increase of \$543. The increase in S&M expenses was due to an increase in personnel related costs, increased business development travel and attendance at tradeshows, and an increase in channel partner commissions.

S&M expenses for NutraDried were \$1,476 for the six months ended March 31, 2022, compared to \$2,263 for the six months March 31, 2021, a decrease of \$787. The decrease in S&M expense was primarily related to a decrease in the use of consultants and professionals for brand marketing services and lower personnel costs, which were offset by more travel and attendance at trade shows.

Research and development

Research and development ("R&D") expenses include the salaries of the pilot plant technicians and scientists, global patent filing and maintenance costs, pilot plant facility costs, and R&D staff travel expenses. R&D expenses also include depreciation expense for R&D equipment and product development activities at NutraDried.

	Three months end	led March 31,	Six months ende	ed March 31,
(\$ '000s)	2022	2021	2022	2021
Research and development	600	463	1,177	1,032
% of revenue	9%	10%	9%	8%

R&D expenses for the six months ended March 31, 2022, were \$1,177 compared to \$1,032 for the six months ended March 31, 2021, an increase of \$145. R&D expenses for the three months ended March 31, 2022, were \$600 compared to \$463 for the three months ended March 31, 2021, an increase of \$137. R&D expenses for 2022 increased relative to 2021 due to additional patent filing and maintenance fees.

We plan to invest in our global patent portfolio for new intellectual property in instances where there is a viable commercial application for the invention, and it strengthens our intellectual property position. R&D expenses fluctuate depending on the timing and filing of additional patents and patent maintenance fees related to the Company's intellectual property, new machine design and NutraDried's new product development activities.



Stock-based compensation

Stock-based compensation expense was \$612 for the six months ended March 31, 2022, compared to \$439 for the six months ended March 31, 2021, an increase of \$173. Stock-based compensation expense was \$378 for the three months ended March 31, 2022, compared to \$185 for the three months ended March 31, 2022, compared to \$185 for the three months ended March 31, 2022, an increase of \$193. The increase relates to the grant of additional stock option awards and Restricted Share Rights ("RSRs") and the related vesting.

	Three months ende	d March 31,	Six months ended March 31,		
(\$ '000s)	2022	2021	2022	2021	
Stock-based compensation	378	185	612	439	

Foreign exchange loss

Foreign exchange loss for the six months ended March 31, 2022, was \$66 compared to \$279 for the six months ended March 31, 2021. Foreign exchange loss for three months ended March 31, 2022 was \$47 compared to \$52 for the three months ended March 31, 2021. The majority of the Company's foreign exchange gain or loss amounts consists of foreign exchange differences driven by our monetary assets and liabilities in US dollars. The fluctuation of foreign exchange is consistent with the Canadian dollar's appreciation or depreciation as measured against the US dollar for each period due to global macroeconomic factors.

	Three months ende	d March 31,	Six months ended	March 31,
(\$ '000s)	2022	2021	2022	2021
Foreign exchange loss	47	52	66	279

Other income

Other income relates to government assistance the Company received from stimulus programs introduced by the Canadian and U.S. government due to the COVID-19 pandemic. For the six months ended March 31, 2022, EnWave received \$147 from the Canadian federal government from the Canada Emergency Wage Subsidy ("CEWS") and Canada Emergency Rent Subsidy ("CERS") programs. The other income recorded in 2021 also relates to COVID-19 relief received under the CERS and CEWS programs, which are non-repayable as long as the Company continues to meet the eligibility criteria.

	Three months ended	March 31,	Six months ended	March 31,
(\$ '000s)	2022	2021	2022	2021
Other income	-	483	147	808



Liquidity and Capital Resources

Working capital

The components of the Company's working capital on March 31, 2022, and September 30, 2021 are:

(\$ '000s)	March 31, 2022	September 30, 2021
Current assets		
Cash and cash equivalents	9,037	11,790
Restricted cash	582	288
Trade receivables	2,485	2,130
Due from customers on contract	883	1,535
Loans receivable, current	496	847
Inventory	6,060	5,722
Prepaids and other receivables	808	833
Income taxes receivable	938	986
	21,289	24,131
Current liabilities		
Borrowings	4	-
Trade and other payables	4,657	4,421
Customer deposits and deferred revenue	1,105	1,323
Current portion of lease liabilities	699	753
Current portion of other liability	65	121
	6,530	6,618
Working capital	14,759	17,513

As at March 31, 2022, the Company had working capital of \$14,759, compared to \$17,513 as at September 30, 2021. As at March 31, 2022, the cash and cash equivalents balance is \$9,037 compared to \$11,790 as at September 30, 2021, a decrease of \$2,753. The Company used \$1,440 of cash to purchase new plant and equipment and used net cash from operating activities of \$986 for the six months ended March 31, 2022.

EnWave had trade receivables of \$731 as at March 31, 2022, compared to \$898 as at September 30, 2021, and NutraDried had trade receivables of \$1,754 as at March 31, 2022, compared to \$1,232 as at September 30, 2021. The decrease in EnWave's trade receivables relates to timing of billing and collection of payments under its equipment sales contracts. The increase of NutraDried's trade receivables relates to timing of collections on account for amounts owing to the Company as at March 31, 2022.

Due from customers on contract to EnWave as at March 31, 2022, was \$883 compared to \$1,535 as at September 30, 2021, with the decrease related to billings made on construction contracts. The amounts due from customers on contract are billed and collected when project specific milestones are reached on each project.

EnWave had inventory of \$3,588 as at March 31, 2022, compared to inventory of \$3,060 at September 30, 2021, an increase of \$528. The inventory of EnWave relates to 10kW machines used for rentals and those under fabrication, as well as components purchased for the fabrication of large machines. EnWave has increased inventory to mitigate supply chain risks and to ensure critical components are available for machine fabrication.

NutraDried had inventory of \$2,472 as at March 31, 2022, compared to \$2,662 as at September 30, 2021, a decrease of \$190. NutraDried's inventory is comprised of food product and packaging supplies. Inventory at NutraDried was slightly lower at March 31, 2022, compared to September 30, 2021, due to higher shipments of product sold in the period.



EnWave had current loans receivable of \$496 as at March 31, 2022, compared to \$847 as at September 30, 2021, that relate to equipment finance loans made to customers under equipment purchase arrangements. The current loans receivable decreased due to repayment of loans during the year according to the scheduled amortization. The loans receivable bear interest at annual interest rates ranging between 6% and 12%, have fixed terms ranging from 3 to 36 months and are amortized with monthly blended payments of interest and principal.

Trade and other payables as at March 31, 2022, includes \$2,968 of trade payables and accrued liabilities related to EnWave, compared to \$2,946 as at September 30, 2021. Trade and other payables for NutraDried were \$1,689 as at March 31, 2022, compared to \$1,475 as at September 30, 2021, with the increase related to increased inventory purchases in the period.

Financing and liquidity

Cash and cash equivalents were \$9,037 as at March 31, 2022, compared to \$11,790 as at September 30, 2021. As at March 31, 2022, we had net working capital of \$14,759 compared to \$17,513 at September 30, 2021. The change in cash consists of:

	Three months end	ed March 31,	Six months ended March 31,		
_(\$ '000s)	2022	2021	2022	2021	
Cash (used in) from operating activities	2,388	(1,264)	(986)	2,964	
Cash used in investing activities	(903)	(815)	(1,337)	(1,430)	
Cash used in financing activities	(844)	(178)	(418)	(923)	

We believe that our current working capital surplus of \$14,759 is sufficient to meet our financing needs, maintain right-sized operations and to grow in the near-term, and achieve planned growth in the long-term. Management will continuously evaluate capital needs and make decisions based on current circumstances. We structure our machine purchase and installation contracts with a deposit payable at the time of order, which provides advanced liquidity for the construction of the machine.

NutraDried has a demand line of credit with a Washington State bank with a credit limit of US\$500 that can be drawn upon to meet short-term liquidity needs. NutraDried had not drawn upon the line of credit as at March 31, 2022.

The Company is targeting to fund operations through cash flows generated from machine sales and royalties from the commercialization of *nutra*REV[®] and *quanta*REV[®] technologies and toll manufacturing opportunities. The Company is not exposed to any externally imposed capital requirements. While we plan to fund our operations through sales of REV[™] machinery, royalty generation, Moon Cheese[®] sales, and toll manufacturing services in the future, there can be no assurance that sufficient revenue will be generated to meet our cash needs.

The ability to achieve our targeted future operating results is based on a number of assumptions that involve significant judgements and estimates, which cannot be assured. If we are unable to achieve our targeted operating results, our liquidity could be adversely impacted. Our operating results could adversely affect our ability to raise additional capital to fund our operations and there is no assurance that debt or equity financing will be available in sufficient amounts, on acceptable terms, or in a timely basis.

Normal course issuer bid

On October 14, 2021, the Company announced the approval of its normal course issuer bid ("NCIB") by the TSX Venture Exchange ("TSXV"). This NCIB commenced on October 29, 2021, and will end on October 28, 2022 and allows the Company to purchase up to 10,778,194 common shares over a period of 12 months, but no more than 2,204,101 shares in any 30-day period. Purchases are made on the open market through the TSXV by Cormark Securities Inc. at the market price of such common shares



at the time of acquisition. At the time of this report, no shares have been purchased or cancelled in the current fiscal year.

Capital expenditures

During the six months ended March 31, 2022, we incurred capital expenditures of \$1,440 related to the acquisition of plant and equipment. NutraDried accounted for \$491 of the capital expenditures for the period with additions to production equipment. EnWave accounted for \$949 of the capital expenditures for the period primarily for assets purchased for the REVworx[™] toll manufacturing facility.

Although we plan to continue to invest in capital equipment as necessary to support our growth, our business is not overly capital intensive. NutraDried will require additional capital expenditures to fund operations in the near term and may require additional capital in the long term to expand production capacity to support future improved distribution of Moon Cheese[®], as well as co-manufacturing contracts.

Contractual obligations

In the normal course of business, the Company enters into contracts that give rise to commitments for future minimum payments. The following table provides information about certain of the Company's significant contractual obligations as at March 31, 2022:

(\$ '000s)	Due within 1 year	Due between 1 - 3 years	Due after 3 years	Total
Financial liabilities	-			
Borrowings	4	8	188	200
Trade and other payables	4,657	-	-	4,657
Lease liabilities	699	1,225	568	2,492
Other liability	65	-	-	65
Total	5,425	1,233	756	7,414

Contingencies

On September 20, 2021, a civil counterclaim commenced against the Company in the Supreme Court of British Columbia by certain former directors and officers of the Company. The counterclaim was filed in response to a civil claim filed by the Company against the former directors and officers. The counterclaim alleges breach of contract and breach of privacy with respect to the cessation of employment of one of the former directors. The Company believes the action to be without merit and intends to defend the counterclaim. No provision has been recognized as of March 31, 2022.

On May 13, 2022, a purported class action proceeding was commenced in the United States District Court for the Southern District of New York against NutraDried, the Company's subsidiary, on behalf of visually impaired or legally blind individuals in the United States that attempted to access the Company's website, and who were allegedly denied access to the equal enjoyment of goods and/or services during the period from May 13, 2019 to May 13, 2022. The complaint alleges, inter alia, that the Company's mooncheese.com website fails to accommodate persons with disabilities according to the *American Disabilities Act*, and unlawfully discriminates to deny such persons the opportunity to participate, or benefit from, the Company's product and services. While this matter is ongoing, the Company intends to vigorously defend against the claims. No provision has been recognized as of March 31, 2022.



Transactions with Related Parties

During the three and six months ended March 31, 2022, the Company paid quarterly directors' fees to its independent directors through a combination of cash and stock-based compensation for their services as directors of the Company.

The table below summarizes the transactions with related parties for the three and six months ended March 31, 2022, and 2021:

(\$ '000s)	Three month	Six months ended		
	N	March 31,		
	2022	2021	2022	2021
	\$	\$	\$	\$
Directors' fees	50	50	100	100
Stock-based compensation	23	51	46	128
	73	101	146	228

Compensation of key management personnel

Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Company and/or its subsidiaries, including any external director of the Company and/or its subsidiaries. Remuneration of key management personnel of the Company, during the three and six months ended March 31, 2022, and 2021 comprises the following expenses:

(\$ '000s)	Three month	Six months ended		
	N	March 31,		
	2022	2021	2022	2021
	\$	\$	\$	\$
Salaries, bonuses, and short-term employee benefits	316	467	1,237	1,072
Stock-based compensation	195	88	329	185
	511	555	1,566	1,257

Critical Accounting Estimates

The preparation of condensed consolidated interim financial statements requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, revenues and expenses. Actual results may differ from these estimates. The Company regularly reviews its estimates and assumptions; however, it is possible that circumstances may arise that may cause actual results to differ from management estimates, and these differences could be material. Estimates and underlying assumptions are reviewed on an ongoing basis, and revisions to estimates are recorded prospectively.

There have been no changes in the Company's critical accounting estimates during the six months ended March 31, 2022. For more information on the Company's accounting policies and key estimates, refer to the note disclosures in the annual consolidated financial statements and MD&A as at and for the year ended September 30, 2021.

Accounting Standards and Amendments Issued and not yet Adopted

The following IFRS standards have been issued by the ISAB and pronouncements that are not expected to have a significant impact have been excluded.



Amendments to IAS 1: Classification of Liabilities as Current or Non-Current

The amendment clarifies the classification requirements to determine if a liability should be presented as current or non-current in the consolidated statement of financial position. Under the new requirement, the assessment of whether a liability is presented as current or non-current is based on the contractual arrangements in place as at the reporting date and does not impact the amount or timing of recognition. The amendment is effective for annual reporting periods beginning on or after January 1, 2022 and is to be applied retrospectively, with earlier application permitted. The Company is currently evaluating the potential impact of these amendments on the Company's consolidated financial statements.

Financial Instruments Risk

The use of financial instruments exposes the Company to a number of risks. These risks include credit risk, liquidity risk, and market risk. The Company has established policies and procedures to manage these risks, with the objective of minimizing the adverse effects that changes in the variable factors underlying these risks could have on the Company's condensed consolidated interim financial statements.

Credit risk

Credit risk is the risk that a counterparty will not meet its obligation under a financial instrument or customer contract, leading to a financial loss being incurred by the Company. Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash and cash equivalents, restricted cash, trade receivables, due from customers on contract and loans receivable. The Company mitigates its exposure to credit loss by maintaining the majority of cash balances with major Canadian financial institutions.

The Company provides credit to its customers in the normal course of business and, as such, has exposure to credit risk in relation to the collection of trade receivables due from customers on contract and loans receivable. Prior to issuing credit, management reviews the customer, taking into account its financial position, historical experience, and other factors. The Company minimizes its credit risk associated with trade receivables and due from customers on contract by maintaining ongoing close contact with customers, by requiring commercial letters of credit, by reviewing individual account balances, and by proactively following up on overdue amounts. The Company maintains a provision for credit losses relating to specific losses estimated on individual exposures. As at March 31, 2022, the Company has recorded a \$nil (2021 - \$nil) provision for expected credit losses.

The Company is exposed to credit risk in trade receivables by way of concentration of credit with a small number of customers. The Company determines its concentration of credit risk if the balance is more than 10% of total revenue or trade receivables. The Company expects these customers to remain as large customers in the future. Significant change in these customer relationships could materially impact the Company's future financial results. The Company seeks and ordinarily obtains progress advances in respect of its construction contracts. The maximum exposure to loss arising from trade receivables and loan receivables are equal to their total carrying amounts.

The Company transacts with a number of Canadian and U.S. banks and other brokerages. Due to the creditworthiness of its counterparties, the Company regards all changes in fair value of foreign exchange derivatives as arising only from changes in market factors, including foreign exchange rates. The Company monitors the exposure to any single counterparty along with its financial position. If it is determined that a counterparty has become materially weaker, the Company will work to reduce its credit exposure to that counterparty.



The following table provides information regarding the aging of receivables as at March 31, 2022:

(\$ '000s)	Neither past due nor impaired	Past due but not impaired				
	0 – 30 days	31 – 90 days	91 – 365 days	Over 365 days		
Trade receivables	2,337	98	50	-		
Due from customers on contract	883	-	-	-		
Loans receivable	837	-	-	-		
Total	4,057	98	50	-		

Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company manages liquidity risk through ongoing management and forecasting of cash flows, budgeting, and equity financings. Cash flow forecasting is performed to monitor cash requirements and to manage capital management decisions. Such forecasting takes into account current and potential customers, contractual obligations and the Company's technology development and commercialization expectations.

The Company's investment policy is to invest its cash in highly liquid short-term interest-bearing investments with varying maturities selected with regards to the expected timing of expenditures from continuing operations. As at March 31, 2022 the Company held foreign exchange derivatives of US\$250 (CA\$312).

The Company attempts to ensure that sufficient funds are available to meet its operating requirements, after taking into account existing cash. The Company manages liquidity risk through the management of its capital structure and financial leverage. As at March 31, 2022, the Company had cash and cash equivalents of \$9,037 to settle current liabilities of \$6,530.

Financial assets maturity table:

(\$ '000s)	0 – 30 days	31 – 90 days	91 – 365 days	Over 365 days
Cash and cash equivalents and restricted cash	9,037	-	582	-
Trade receivables	2,485	-	-	-
Due from customers on contract	650	233	-	-
Loans receivable	66	139	297	335
Income taxes receivable	-	-	938	-
Total	12,238	372	1,817	335

Financial liabilities, excluding other liability, maturity table:

(\$ '000s)	0 – 30 days	31 – 90 days	91 – 365 days	Over 365 days
Borrowings	-	-	4	196
Trade and other payables	4,214	-	443	-
Customer deposits and deferred revenue	1,105	-	-	-
Lease liabilities	54	108	537	1,793
Total	5,373	108	984	1,989



Market risk

Market risk is the risk that the fair value of future cash flows of the Company will fluctuate due to changes in interest rates and foreign currency exchange rates.

Interest rate risk

Interest rate risk refers to the risk that the value of a financial instrument or cash flows associated with the instrument will fluctuate due to changes in market interest rates. The Company is exposed to interest rate risk from the interest rate impact on cash and cash equivalents and restricted cash. The Company earns interest on deposits based on current market interest rates, which during the three months ended March 31, 2022, ranged from 0.65% to 1.10%. A 1% change in interest rates would affect the results of operations by approximately \$42.

Foreign exchange risk

The Company is exposed to the following foreign exchange risks related to the fluctuation of foreign exchange rates:

- (i) the Company operates in the United States and a portion of its expenses are incurred in US dollars; and
- (ii) the Company is exposed to currency risk through contracts with customers denominated in US dollars.

A significant change in the currency exchange rate of the Canadian dollar relative to the US dollar could influence the Company's results of operations. As at March 31, 2022, all of the Company's liquid assets and liabilities were held in Canadian dollars and US dollars.

The Company enters into foreign exchange derivative contracts when appropriate to minimize exposure to foreign currencies when appropriate. As at March 31, 2022, the Company held foreign exchange contracts of US\$250 (CA\$312). The fair values of the foreign exchange derivatives are recurring measurements and are determined whenever possible based on observable market data. If observable market data on the financial derivatives is not available, the Company uses observable spot and forward foreign exchange rates to estimate their fair values.

A change in the value of the Canadian dollar by 10% relative to foreign currencies the Company is exposed to would have affected the Company's net loss for the six months ended March 31, 2022, and 2021 as follows:

(\$ '000s)	2022 \$	2021 \$
US dollar	315	61

Capital management

The Company's objectives when managing capital are to safeguard its ability to continue as a going concern and to maintain a flexible capital structure, which optimizes the cost of capital at an acceptable risk.

In the management of capital, the Company includes the components of equity attributable to common shareholders. The Company manages the capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust its capital structure, the Company may attempt to issue new shares, issue debt and acquire or dispose of assets. In order to facilitate the management of its capital requirements, the Company prepares annual expenditure budgets that are updated as necessary depending on various factors, including successful capital deployment and general industry conditions.



There were no changes in the Company's approach to capital management in the period. Neither the Company nor any of its subsidiaries are subject to externally imposed capital requirements.

Non-IFRS Financial Measures

In addition to results reported in accordance with IFRS, EnWave also uses certain non-IFRS financial measures as supplemental indicators of its financial and operating performance. Non-IFRS financial measures include NutraDried Royalties and Adjusted EBITDA. Management believes that these supplementary financial measures reflect the Company's ongoing business in a manner that allows for meaningful period-to-period comparisons and analysis of business trends.

We reference the NutraDried royalty payment to the Company, which is an intercompany transaction that is eliminated upon consolidation from revenue as reported in the Company's condensed consolidated interim financial statements. The Company reports the royalty payments to itself from NutraDried because it provides the amount of royalties being paid by NutraDried under its license agreement with the Company. The intercompany royalty revenue does not have any standardized meaning under IFRS and therefore may not be comparable to other similar measures presented by other issuers.

The table below provides a reconciliation of the NutraDried royalty to revenues as reported in the Company's condensed consolidated interim financial statements:

(\$ '000s)	Jun 30, 2020	Sep 30, 2020	Dec 31, 2020	Mar 31, 2021	Jun 30, 2021	Sep 30, 2021	Dec 31, 2021	Mar 31, 2022
NutraDried Royalty	236	670	340	166	218	118	137	341
Intercompany Revenue Adjustment ⁽¹⁾	(236)	(670)	(340)	(166)	(218)	(118)	(137)	(341)
Revenues ⁽²⁾	5,998	10,784	7,533	4,686	7,351	6,906	6,297	6,881
Revenues	5,998	10,784	7,533	4,686	7,351	6,906	6,297	6,881

Notes:

(1) Adjustment to eliminate intercompany revenue from the condensed consolidated interim financial statements.

(2) Revenues as reported in the Company's condensed consolidated interim statements of loss for the period.

We define Adjusted EBITDA as earnings before deducting amortization and depreciation, stock-based compensation, foreign exchange gain or loss, finance expense or income, income tax expense or recovery and non-recurring impairment, restructuring and severance charges and government assistance. We believe that Adjusted EBITDA is a useful measure as it provides an indication of the operational results of the business. We consider Adjusted EBITDA to be a key measure as it provides an alternative measure of profitability before taking into account the Company's non-cash expenses, and it is used by management to measure performance; however, this metric is not defined under IFRS. As a result, this amount may not be comparable to those calculated by other issuers.

Below is a reconciliation of our quarterly net (loss) income to Adjusted EBITDA for the last eight quarters:

	Jun	Sep	Dec	Mar	Jun	Sep	Dec	Mar
(\$ '000s)	30, 2020	30, 2020	31, 2020	31, 2021	30, 2021	30, 2021	31, 2021	31, 2022
Net (loss) income after income tax	(1,166)	1	(1,371)	(2,286)	670	(1,138)	(253)	(2,386)
Amortization and depreciation ⁽¹⁾	513	759	670	594	639	610	447	735
Stock-based compensation ⁽²⁾	314	227	254	185	198	187	234	378
Foreign exchange loss (gain) ⁽³⁾	151	92	227	52	(275)	(19)	19	47
Finance (income) expense net ⁽⁴⁾	(27)	(29)	4	(3)	-	(8)	1	8
Income tax expense (recovery)	(129)	(101)	(370)	(718)	(70)	451	-	-
Non-recurring impairment and restructuring costs ⁽⁵⁾	-	-	-	691	-	-	-	-
Government assistance ⁽⁶⁾	(690)	(929)	(325)	(483)	(225)	(306)	(147)	-
Adjusted EBITDA	(1,034)	20	(911)	(1,968)	937	(223)	301	(1,218)

Notes:


- (1) Amortization and depreciation of property, plant and equipment and intangible assets is a non-cash expense and therefore does not require any cash outlay by the Company.
- (2) These include awards that are settled though shares issued from treasury and generally do not require any cash outlay by the Company and are excluded to provide investors with a greater visibility to the underlying performance of operations.
- (3) Foreign exchange gains or losses arise from fluctuations in foreign exchange rates of the currencies we transact in, which are driven by macro-economic conditions that are generally not reflective of our business operations.
- (4) Finance income, net is total finance income net of finance expenses and does not relate to costs to operate our ongoing operations.
- (5) Non-recurring impairment and restructuring costs are not included in Adjusted EBITDA as they relate to non-recurring costs that do not form part of the costs to operate our ongoing operations and are not expected to reoccur in the future.
- (6) Government grants are excluded as they relate to grants received by the Company from governments under COVID-19 relief and stimulus programs, they do not relate to revenues received from business operations and are non-recurring.

Non-IFRS financial measures do not have any standardized meaning prescribed by IFRS, and other companies may calculate these measures differently. The presentation of non-IFRS financial measures is intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS.

Forward-looking Statements

Certain statements in this MD&A constitute forward-looking statements, based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, R&D, market position, expected expenditures and financial results are forward-looking statements. Forward-looking statements are statements about the future and are inherently uncertain, and actual achievements of the Company and other results and occurrences may differ from those reflected in the forward-looking statements due to a variety of risks, uncertainties and other factors, including, without limitation:

 EnWave's ultimate success in selling, licensing or generating a sustainable royalty stream from its *nutra*REV[®] and *quanta*REV[®] technologies in the cannabis and food industries will depend, in large part, on whether these targeted markets view our technologies ("the EnWave technologies") as safe, effective and economically beneficial. Market acceptance will also depend on the Company's ability to demonstrate that the EnWave technologies are attractive alternatives to existing options. If the Company fails to demonstrate feasibility, commercially viable scale that yields acceptable product quality and equipment performance standards, or



ΝWλVF

F

- EnWave's technologies targeted for use in the cannabis and pharmaceutical industries will be subject to regulatory approval by a number of government entities and legal systems. Technology development within this regulatory and legal framework may take a number of years and may involve substantial expenditures that vary for each jurisdiction. Any delays in obtaining regulatory and/or legal approval would have an adverse impact on the Company's ability to earn future revenues.
- R&D activities for new technologies are costly and may not be successful. There is no assurance that any of EnWave's technologies will be approved for marketing by the FDA or the equivalent regulatory agency of any other country. There is also no assurance that the Company will be able to generate additional technology candidates for its pipeline, either through internal R&D, or through the in-licensing or acquisition of other technologies. Even if a technology is approved for marketing by the applicable regulatory agency, there is no assurance that the Company will be able to ultimately deliver this technology on a commercial scale or obtain approvals for other technology platforms in the development pipeline.
- EnWave's business is dependent upon securing proprietary rights to its technologies and the Company may be subject to intellectual property infringement claims by others or may not ultimately receive issued patents in all jurisdictions where patents are pending or for new applications.
- EnWave is partially dependent on third-party groups for developing its technology. The inability to design and build commercial scale technology in a timely manner could result in significant delays in development and commercialization of its technologies, which could adversely affect the Company's business, financial condition and results of operations.
- EnWave depends on third-party collaborators to license, co-develop and jointly commercialize some of its technologies. There is no guarantee these third-parties will meet the Company's expectations or be able to find commercial opportunities with the technology to support successful commercialization of the EnWave technologies.
- EnWave's business success and progress is dependent upon securing additional funding to expand its business and develop new technologies. If the Company cannot raise capital from investors or secure grants, it may limit the Company's business expansion, ongoing testing programs, regulatory approvals and ultimately impact its ability to commercialize its technologies.
- The impact of the COVID-19 pandemic on the Company's business, operations, capital resources and/or financial results. See the *"Risk Factors"* section in the Company's Annual Information Form for further information about related risks and uncertainties.

Actual results could, however, be substantially different due to the risks and uncertainties associated with and inherent to EnWave's business, as more particularly described in the *"Risk Factors"* section of the Company's 2021 Annual Information Form. Additional risks and uncertainties applicable to the forward-looking statements set out herein include, but are not limited to: fluctuations in EnWave's quarterly operating results; fluctuations in EnWave's operating and capital expenses; fluctuations in foreign exchange rates and interest rates that negatively impact EnWave; new or increased competition from other companies developing microwave vacuum technology; the inaccuracy of industry data and projections relied upon by EnWave; interruptions to EnWave's supply chain for key machine components; EnWave will become involved in material litigation; material defects and component quality of parts and raw materials sourced from EnWave suppliers; unforeseen changes to food safety and compliance regulations in the U.S. food processing industry; R&D efforts may not result in the creation of new or enhanced products in a timely or cost-effective fashion or at all; EnWave's royalty partners' and licensees' unwillingness to continue doing business with EnWave on favourable



Six months ended March 31, 2022 - dated May 26, 2022

terms or at all: EnWave's business development efforts may not result in increased vertical and market penetration in the global dehydration industry; EnWave's technology may not function as intended or be suitable for the end users it is intended for; unknown or unexpected defects with EnWave's technology that are not correctable in a timely or cost-effective fashion or at all: necessary additional financing may not be available on favourable terms or at all; inability to recruit and retain gualified personnel; legal or regime changes, including changes to import and export requirements of foreign jurisdictions; political risk of domestic and foreign nations; war, terrorism, rebellion, revolt, protests, or other civil conflict; unionization, strikes or labour unrest; the global economic climate; general market trends; EnWave's intellectual property may not be sufficiently protected against third party infringement or misappropriation; EnWave's products may materially infringe on a third party's intellectual property rights; the ongoing ability and desirability of licensees to continue paying EnWave patent licensing royalties on a timely basis or at all; material litigation may arise; material unexpected costs related to EnWave's technology liability or warranty; loss of Starbucks, Costco or other major customer(s) of NutraDried; produce recalls or other food safety issues and regulatory actions could arise; information technology data and security breaches; fire, flood, earthquake, or other natural events; failure to obtain necessary permits, certifications, and authorizations; foreign currency fluctuations; dairy and other food commodity pricing fluctuations; share price volatility; unfavourable legal environments for the deployment of REV[™] machinery for cannabis processing in certain jurisdictions; deficiencies in accounting policies or internal controls and procedures over financial reporting; insufficiency of insurance; unavailability of certain tax credits; unexpected tax liabilities; business interruptions and/or shutdowns caused by the COVID-19 pandemic.

Although EnWave has attempted to identify factors that may cause actual actions, events or results to differ materially from those disclosed in the forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, predicted, estimated or intended. Also, many of the factors are beyond the control of EnWave. Accordingly, readers should not place undue reliance on forward-looking statements. EnWave undertakes no obligation to reissue or update any forward-looking statements as a result of new information or events after the date hereof except as may be required by law. All forward-looking statements contained in this MD&A are qualified by this cautionary statement.

Off-balance Sheet Arrangements

As of the date of this MD&A, the Company had a US\$205 (CA\$256) letter of credit issued in favour of a customer related to an equipment purchase contract. There are no other material off-balance sheet arrangements.

Capital Structure and Outstanding Share Data

The common shares, warrants, options and RSRs outstanding and exercisable as at the following dates are shown below:

	March 31, 2022		May 26, 2022	
		Weighted		Weighted
		average		average
		exercise		exercise
	price		price	
	Number	\$	Number	\$
Common shares outstanding	110,380,055	N/A	110,380,055	N/A
Options				
Outstanding	8,468,267	1.34	8,458,267	1.34
Exercisable RSRs	5,619,693	1.51	5,695,935	1.51
Outstanding	815,000	1.02	815,000	1.02
Warrants				
Investor warrants	5,012,202	1.50	5,012,202	1.50



As of the date of this MD&A, the Company has 110,380,055 common shares issued and outstanding. We maintain a Stock Option Plan (the "Option Plan") that enables us to grant options to directors, officers, employees and consultants. We maintain a Restricted Share Rights Plan (the "RSR Plan") that enables us to grant RSRs to directors, officers, employees and consultants. The Option Plan and RSR Plan permits the granting of compensation securities up to an aggregate maximum of 10% of our issued and outstanding common shares from time to time on a non-diluted basis, and the maximum number of RSRs granted thereunder is further limited to 1,895,000.

Other MD&A Requirements

Information pursuant to National Instrument 51-102.

Copies of all previously published financial statements, MD&A, meeting materials, press releases, etc., are available on Company's website at <u>www.enwave.net</u>, or on the SEDAR website at <u>www.sedar.com</u>.

Directors Senior Officers Position John P.A. Budreski John P.A. Budreski **Executive Chairman** Brent Charleton Brent Charleton, CFA President and Chief Executive Officer Dr. Stewart Ritchie Dan Henriques, CPA, CA Chief Financial Officer Mary C. Ritchie Stephen Sanford Patrick Turpin Pablo Cussatti

Directors and officers as at the date of this MD&A:

Contact information:

Corporate, Strategic and Investor Inquiries	Administration and Finance	
Brent Charleton, CFA	Dan Henriques, CPA, CA	
President and Chief Executive Officer	Chief Financial Officer	
Telephone (+1) 778 378 9616	Telephone (+1) 604 835 5212	
<u>bcharleton@enwave.net</u>	<u>dhenriques@enwave.net</u>	
